Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

May 20, 2023
By Ben Kong, PharmD, BCPS
News
Article
OncologyONCOLOGY Vol 37, Issue 5
Volume 37
Issue 5
Pages: 216-217

Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.

A function of immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, is to allow normal tissues to coexist with the immune system and avoid triggering a destructive response. When PD-1 (found on T cells) is bound to PD-L1 (found on normal tissue), it dampens T-cell activation.1 It is now recognized that tumors can also express PD-L1, gaining the ability to escape detection and be allowed to proliferate. Thus, the role of PD-L1 as a biomarker has emerged, and there is interest in the therapeutic opportunity to block the PD-1/PD-L1 interaction.

In 2014, pembrolizumab (Keytruda) was the first PD-1 inhibitor to receive FDA approval for use in melanoma. This was further expanded in 2017 and 2020 to tumors with microsatellite instability–high status and tumor mutational burden (TMB) greater than 10 mut/Mb, respectively. Since then, other PD-1/PD-L1 inhibitors have been approved in various diseases, such as nivolumab (Opdivo), atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi). When a response is seen, it tends to be durable and prolonged. Regarding immune-related adverse effects, they can affect any organ system and lead to reactions such as rash, diarrhea, endocrinopathies, musculoskeletal pain, pneumonitis, and more.

The authors of “Biomarkers for Response to Anti–PD-1/ PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis” performed a comprehensive review of 100 studies, encompassing approximately 18,000 patients to address the role of 9 predictive biomarkers across tumor types. With a large data set available to conduct robust statistical analysis, their findings suggest that TMB, PD-L1 immunohistochemistry (IHC), and multiplex IHC/immunofluorescence were sensitive in predicting response across all tumor types, although the authors acknowledge heterogeneity in study design and limited study size. Some of the complexities and nuances may pertain to the assay and clinical interpretation of immune therapies.

Among the antibodies available to assess PD-L1 expression, 4 are associated with the clinical indication (eg, 22C3/pembrolizumab, 28-8/nivolumab, SP263/durvalumab, and SP142/atezolizumab). When interpreting PD-L1 IHC, a number of additional factors need consideration besides the PD-L1 clone, such as the control, tissue fixation, adequate number of tumor cells, and PD-L1 scoring method (tumor proportion score, combined positive score, tumor cell/ immune cell).2,3

The TMB captures somatic alterations within a genomic sequence, and higher values are associated with response to immune therapy. Although the standard method to determine TMB is generally derived from whole exome or genome sequencing, it is not routinely performed due to cost and turnaround. Instead, targeted panels are widely adopted and used to identify oncogenic mutations and estimate TMB. Because of the potential discrepancy, a study explored the performance of panel-based assay compared with whole exome sequencing and observed that variabilities exist among the 11 participating laboratories, leading to either underestimation or overestimation of TMB—likely due to differences in panel size and bioinformatic algorithms.4

The RECIST Working Group has provided guidance in defining and measuring responses to cancer therapies. Unlike traditional therapies, immune modulators tend to have a different pattern of response, which led to the development of iRECIST.5 Specifically, immune modulators can elicit either a delayed clinical response or pseudoprogression—the latter being a phenomenon in which the initial imaging assessment may show new lesions or existing tumors that appear larger, followed by a delayed clinical response. The distinction between pseudoprogression and true progression remains a challenge, so it is currently recommended to continue treatment until the next imaging assessment.

Moving forward, a future toward standardization of analytical methods and interpretation would assist in reducing certain aspects of heterogeneity that are naturally inherent in studies. Doing so would pave the way to better understanding the predictive potential of biomarkers and identifying the patient who may benefit the most from treatment.

DISCLOSURES: Kong is a consultant for Clarified Precision Medicine.

AFFILIATIONS: Oregon Health & Science University and Oregon Health & Science University Knight Cancer Institute

CORRESPONDING AUTHOR(S):

Ben Kong, PharmD, BCPS
Clinical Pharmacy Specialist
Oregon Health & Science University
Email: kong@ohsu.edu
ORCID: 0000-0002-9019-6961

References

  1. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-245. doi:10.1038/ni1443
  2. Chebib I, Mino-Kenudson M. PD-L1 immunohistochemistry: clones, cutoffs, and controversies. APMIS. 2022;130(6):295-313. doi:10.1111/apm.13223
  3. Prince EA, Sanzari JK, Pandya D, Huron D, Edwards R. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis Oncol. 2021;5:953-973. doi:10.1200/PO.20.00412
  4. Merino DM, McShane LM, Fabrizio D, et al; TMB Harmonization Consortium. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e000147. doi:10.1136/jitc-2019-000147
  5. Seymour L, Bogaerts J, Perrone A, et al; RECIST Working Group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143-e152. doi:10.1016/S1470-2045(17)30074-8. Published correction appears in Lancet Oncol. May 20, 2019
Download Issue PDFDownload PDF
Articles in this issue

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report
The Painful Problem of Biosimilars in the Clinic
The Painful Problem of Biosimilars in the Clinic
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment
Recent Videos
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content
Advertisement

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Caroline Seymour
April 29th 2025
Article

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.

Related Content
Advertisement

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Caroline Seymour
April 29th 2025
Article

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.